Cargando…

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

BACKGROUND: The aim of this study was to determine the presence and the intensity of humoral immunity to melanoma-associated antigens: tyrosinase and melanin, in patients with melanoma, in persons with vitiligo and in control healthy people. METHODS: The study involved 63 patients with melanoma and...

Descripción completa

Detalles Bibliográficos
Autores principales: Đorđić, Marija, Matić, Ivana Z, Filipović-Lješković, Ivana, Džodić, Radan, Šašić, Miomir, Erić-Nikolić, Aleksandra, Vuletić, Ana, Kolundžija, Branka, Damjanović, Ana, Grozdanić, Nađa, Nikolić, Srđan, Pralica, Janko, Dobrosavljević, Danijela, Rašković, Sanvila, Andrejević, Slađana, Juranić, Zorica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457868/
https://www.ncbi.nlm.nih.gov/pubmed/22834951
http://dx.doi.org/10.1186/1472-6882-12-109
_version_ 1782244580032249856
author Đorđić, Marija
Matić, Ivana Z
Filipović-Lješković, Ivana
Džodić, Radan
Šašić, Miomir
Erić-Nikolić, Aleksandra
Vuletić, Ana
Kolundžija, Branka
Damjanović, Ana
Grozdanić, Nađa
Nikolić, Srđan
Pralica, Janko
Dobrosavljević, Danijela
Rašković, Sanvila
Andrejević, Slađana
Juranić, Zorica
author_facet Đorđić, Marija
Matić, Ivana Z
Filipović-Lješković, Ivana
Džodić, Radan
Šašić, Miomir
Erić-Nikolić, Aleksandra
Vuletić, Ana
Kolundžija, Branka
Damjanović, Ana
Grozdanić, Nađa
Nikolić, Srđan
Pralica, Janko
Dobrosavljević, Danijela
Rašković, Sanvila
Andrejević, Slađana
Juranić, Zorica
author_sort Đorđić, Marija
collection PubMed
description BACKGROUND: The aim of this study was to determine the presence and the intensity of humoral immunity to melanoma-associated antigens: tyrosinase and melanin, in patients with melanoma, in persons with vitiligo and in control healthy people. METHODS: The study involved 63 patients with melanoma and 19 persons with vitiligo. Control group consisted up to 41 healthy volunteers. Mushroom tyrosinase and synthetic melanin were used as the antigens. RESULTS: ELISA test showed significantly (p < 0.0000004 and p < 0.04) lower levels of IgM anti-tyrosinase autoantibodies, in melanoma and vitiligo patients respectively, compared to controls. Although there was no significant difference between the levels of IgA anti-melanin autoantibodies in melanoma or vitiligo patients in comparison with controls, the enhanced concentrations of anti-melanin IgA autoantibodies were preferentially found in melanoma patients with metastatic disease. Significantly high percentage in the Fc alphaRI (CD89) positive cells was determined in melanoma patients (p < 0.002 and p < 0.008) in comparison to that found in healthy people or in patients with vitiligo, in the already mentioned order, pointing that IgA dependent cellular cytotoxicity is not important for the immune action against melanoma, even more that it is included in some immune suppression. Levels of IgG autoantibodies to mentioned antigens in melanoma patients although low were not significantly lower from controls. These findings analyzed together with the statistically significant low percentage of FcgammaRIII, (CD16) positive immunocompetent cells (p < 0.0007 and p < 0.003), which was found in patients with melanoma compared with healthy or vitiligo people respectively, and statistically significant low percentage of (CD16 + CD56+) natural killer (NK) cells (p < 0.005) found in melanoma patients in comparison to healthy controls pointed to the low probability for anti-melanoma IgG mediated, antibody mediated cellular cytotoxicity, (ADCC) and NK cytotoxicity. Moreover the ratio of the percentages of granulocytes and percentage of lymphocytes was statistically higher in patients with melanoma in relation to healthy people as well as to people with vitiligo (p < 0.0007 and p < 0.05 respectively). CONCLUSION: Autoantibodies to tyrosinase and to melanin which are found even in healthy people, point that consummation of edible mushrooms that carry the antigen tyrosinase and melanin, could influence the humoral anti-melanoma immune response. Levels of different immunoglobulin classes of anti-melanin and anti-tyrosinase antibodies varied depending on the presence and the stage of studied diseases. Besides, the statistically enhanced ratio of the percentages of granulocytes and percentage of lymphocytes, together with statistically decreased percentage of NK cells is found in analyzed melanoma patients.
format Online
Article
Text
id pubmed-3457868
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34578682012-09-26 Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo Đorđić, Marija Matić, Ivana Z Filipović-Lješković, Ivana Džodić, Radan Šašić, Miomir Erić-Nikolić, Aleksandra Vuletić, Ana Kolundžija, Branka Damjanović, Ana Grozdanić, Nađa Nikolić, Srđan Pralica, Janko Dobrosavljević, Danijela Rašković, Sanvila Andrejević, Slađana Juranić, Zorica BMC Complement Altern Med Research Article BACKGROUND: The aim of this study was to determine the presence and the intensity of humoral immunity to melanoma-associated antigens: tyrosinase and melanin, in patients with melanoma, in persons with vitiligo and in control healthy people. METHODS: The study involved 63 patients with melanoma and 19 persons with vitiligo. Control group consisted up to 41 healthy volunteers. Mushroom tyrosinase and synthetic melanin were used as the antigens. RESULTS: ELISA test showed significantly (p < 0.0000004 and p < 0.04) lower levels of IgM anti-tyrosinase autoantibodies, in melanoma and vitiligo patients respectively, compared to controls. Although there was no significant difference between the levels of IgA anti-melanin autoantibodies in melanoma or vitiligo patients in comparison with controls, the enhanced concentrations of anti-melanin IgA autoantibodies were preferentially found in melanoma patients with metastatic disease. Significantly high percentage in the Fc alphaRI (CD89) positive cells was determined in melanoma patients (p < 0.002 and p < 0.008) in comparison to that found in healthy people or in patients with vitiligo, in the already mentioned order, pointing that IgA dependent cellular cytotoxicity is not important for the immune action against melanoma, even more that it is included in some immune suppression. Levels of IgG autoantibodies to mentioned antigens in melanoma patients although low were not significantly lower from controls. These findings analyzed together with the statistically significant low percentage of FcgammaRIII, (CD16) positive immunocompetent cells (p < 0.0007 and p < 0.003), which was found in patients with melanoma compared with healthy or vitiligo people respectively, and statistically significant low percentage of (CD16 + CD56+) natural killer (NK) cells (p < 0.005) found in melanoma patients in comparison to healthy controls pointed to the low probability for anti-melanoma IgG mediated, antibody mediated cellular cytotoxicity, (ADCC) and NK cytotoxicity. Moreover the ratio of the percentages of granulocytes and percentage of lymphocytes was statistically higher in patients with melanoma in relation to healthy people as well as to people with vitiligo (p < 0.0007 and p < 0.05 respectively). CONCLUSION: Autoantibodies to tyrosinase and to melanin which are found even in healthy people, point that consummation of edible mushrooms that carry the antigen tyrosinase and melanin, could influence the humoral anti-melanoma immune response. Levels of different immunoglobulin classes of anti-melanin and anti-tyrosinase antibodies varied depending on the presence and the stage of studied diseases. Besides, the statistically enhanced ratio of the percentages of granulocytes and percentage of lymphocytes, together with statistically decreased percentage of NK cells is found in analyzed melanoma patients. BioMed Central 2012-07-26 /pmc/articles/PMC3457868/ /pubmed/22834951 http://dx.doi.org/10.1186/1472-6882-12-109 Text en Copyright ©2012 Đorđić et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Đorđić, Marija
Matić, Ivana Z
Filipović-Lješković, Ivana
Džodić, Radan
Šašić, Miomir
Erić-Nikolić, Aleksandra
Vuletić, Ana
Kolundžija, Branka
Damjanović, Ana
Grozdanić, Nađa
Nikolić, Srđan
Pralica, Janko
Dobrosavljević, Danijela
Rašković, Sanvila
Andrejević, Slađana
Juranić, Zorica
Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
title Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
title_full Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
title_fullStr Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
title_full_unstemmed Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
title_short Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
title_sort immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457868/
https://www.ncbi.nlm.nih.gov/pubmed/22834951
http://dx.doi.org/10.1186/1472-6882-12-109
work_keys_str_mv AT đorđicmarija immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT maticivanaz immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT filipovicljeskovicivana immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT dzodicradan immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT sasicmiomir immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT ericnikolicaleksandra immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT vuleticana immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT kolundzijabranka immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT damjanovicana immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT grozdanicnađa immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT nikolicsrđan immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT pralicajanko immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT dobrosavljevicdanijela immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT raskovicsanvila immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT andrejevicslađana immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo
AT juraniczorica immunitytomelaninandtotyrosinaseinmelanomapatientsandinpeoplewithvitiligo